AA
AMAG

ALPS Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

ALPS Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-67,599
Closed -$781K – 872
2019
Q3 		$781K Sell
67,599
-3,068
-4% -$32.3K 0.01% 351
2019
Q2 		$706K Sell
70,667
-13,178
-16% -$142K 0.01% 439
2019
Q1 		$1.08M Buy
83,845
+4,036
+5% +$60.1K 0.01% 310
2018
Q4 		$1.21M Buy
79,809
+18,806
+31% +$358K 0.01% 267
2018
Q3 		$1.22M Buy
61,003
+11,187
+22% +$255K 0.01% 331
2018
Q2 		$971K Buy
49,816
+4,096
+9% +$90.6K 0.01% 343
2018
Q1 		$921K Sell
45,720
-8,047
-15% -$136K 0.01% 329
2017
Q4 		$712K Buy
53,767
+19,015
+55% +$287K ﹤0.01% 324
2017
Q3 		$641K Buy
34,752
+3,119
+10% +$58.1K ﹤0.01% 327
2017
Q2 		$582K Buy
31,633
+2,091
+7% +$41.4K ﹤0.01% 375
2017
Q1 		$666K Sell
29,542
-3,334
-10% -$79.8K ﹤0.01% 262
2016
Q4 		$1.14M Sell
32,876
-10,664
-24% -$319K 0.01% 209
2016
Q3 		$1.07M Sell
43,540
-22,416
-34% -$560K 0.01% 221
2016
Q2 		$1.58M Buy
65,956
+8,218
+14% +$188K 0.01% 186
2016
Q1 		$1.35M Buy
57,738
+2,145
+4% +$50.9K 0.01% 174
2015
Q4 		$1.68M Buy
55,593
+45,716
+463% +$1.48M 0.02% 187
2015
Q3 		$3.92K Buy
+9,877
New +$613K ﹤0.01% 629

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ALPS Advisors's AMAG Position: Q4 2019 in Review

ALPS Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2019, closing a stake of 67,599 shares — an estimated $781K sold.

ALPS Advisors first reported a position in AMAG in Q3 2015 and held it in 17 quarters. The position peaked at $1.68M in Q4 2015. 134 funds tracked by Wall St. Rank hold AMAG as of Q4 2019.

  • ALPS Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • ALPS Advisors sold 67,599 AMAG Pharmaceuticals shares in Q4 2019, an estimated $781K.
  • ALPS Advisors first reported a position in AMAG Pharmaceuticals in Q3 2015 and held it in 17 quarters.
  • ALPS Advisors's AMAG Pharmaceuticals position peaked at $1.68M in Q4 2015.
  • 134 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2019.

Based on ALPS Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.